Print PDF

Sheppard Mullin Represented Valkyrie Clinical Trials in Strategic Investment by Flourish Research

The firm advised Valkyrie Clinical Trials (Valkyrie) in its strategic partnership with Flourish Research (Flourish), a leading multi-site clinical trial organization. Flourish's investment marks a significant expansion of its presence in oncology research and strengthens its footprint in Southern California. Valkyrie Clinical Trials, founded by Dr. David Berz and operating three sites in Los Angeles, provides cutting-edge cancer therapies and access to more than 200,000 cancer patients through a diverse referral network.

This strategic partnership will enable Valkyrie to accelerate growth and broaden access to innovative oncology trials by leveraging Flourish’s national network and infrastructure. The collaboration also provides Flourish with deep expertise and comprehensive access to the oncology sector, supporting its continued nationwide expansion and commitment to developing advanced cancer treatments.

The Sheppard Mullin deal team was led by partner Aytan Dahukey and associates Karl Buhler and Bryan Lanfranco Ferreyra.

Read the press release here.

Practice Areas

Industries

Jump to Page

By scrolling this page, clicking a link or continuing to browse our website, you consent to our use of cookies as described in our Cookie and Advertising Policy. If you do not wish to accept cookies from our website, or would like to stop cookies being stored on your device in the future, you can find out more and adjust your preferences here.